This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Granger, C. B. Search for Related Content PubMed PubMed Citation Articles by Granger, C. B. Related Collections Other Ethics and Policy Genetics of cardiovascular disease Other Vascular biology Other diagnostic testing Genomics

(Circulation. 2004;109:1697-1703.)
© 2004 American Heart Association, Inc.

Special Report

National Heart, Lung, and Blood Institute Clinical Proteomics Working Group Report

Christopher B. Granger, MD; Jennifer E. Van Eyk, PhD; Stephen C. Mockrin, PhD; N. Leigh Anderson, PhD, on behalf of the Working Group Members^*

Correspondence to Christopher B. Granger, MD, Box 3409, Duke University Medical Center, Durham, NC 27710.

The National Heart, Lung, and Blood Institute (NHLBI) Clinical Proteomics Working Group was charged with identifying opportunities and challenges in clinical proteomics and using these as a basis for recommendations aimed at directly improving patient care. The group included representatives of clinical and translational research, proteomic technologies, laboratory medicine, bioinformatics, and 2 of the NHLBI Proteomics Centers, which form part of a program focused on innovative technology development. This report represents the results from a one-and-a-half-day meeting on May 8 and 9, 2003. For the purposes of this report, clinical proteomics is defined as the systematic, comprehensive, large-scale identification of protein patterns ("fingerprints") of disease and the application of this knowledge to improve patient care and public health through better assessment of disease susceptibility, prevention of disease, selection of therapy for the individual, and monitoring of treatment response.

Key Words: proteins • diagnosis • prognosis • genetics • plasma

This article has been cited by other articles:

				C. D. Ochoa, H. Baker, S. Hasak, R. Matyal, A. Salam, C. A. Hales, W. Hancock, and D. A. Quinn Cyclic Stretch Affects Pulmonary Endothelial Cell Control of Pulmonary Smooth Muscle Cell Growth Am. J. Respir. Cell Mol. Biol., July 1, 2008; 39(1): 105 - 112. [Abstract] [Full Text] [PDF]

				D. T. Miller, P. M. Ridker, P. Libby, and D. J. Kwiatkowski Atherosclerosis: The Path From Genomics to Therapeutics J. Am. Coll. Cardiol., April 17, 2007; 49(15): 1589 - 1599. [Abstract] [Full Text] [PDF]

				T. Pisitkun, R. Johnstone, and M. A. Knepper Discovery of Urinary Biomarkers Mol. Cell. Proteomics, October 1, 2006; 5(10): 1760 - 1771. [Abstract] [Full Text] [PDF]

				I. Dalle-Donne, R. Rossi, R. Colombo, D. Giustarini, and A. Milzani Biomarkers of Oxidative Damage in Human Disease Clin. Chem., April 1, 2006; 52(4): 601 - 623. [Abstract] [Full Text] [PDF]

				G. S. Ginsburg, M. P. Donahue, and L. K. Newby Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1615 - 1627. [Abstract] [Full Text] [PDF]

				N. L. Anderson The Roles of Multiple Proteomic Platforms in a Pipeline for New Diagnostics Mol. Cell. Proteomics, October 1, 2005; 4(10): 1441 - 1444. [Full Text] [PDF]

				W.R. MacLellan, P. Ping, and T. Vondriska Heart disease leaves its mark: Proteomics-based biosignatures in acute coronary syndromes J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1584 - 1586. [Full Text] [PDF]